GB-102Wet age-related macular degeneration
New formulation - repurposed medicine
Development and Regulatory status
PII Clinical Trials
A small molecule receptor tyrosine kinase inhibitor that potently blocks several intracellular receptors associated with angiogenesis, proliferation, vascular permeability and fibrosis, formulated as a depot injection to be administered twice-yearly .
The estimated prevalence of AMD in the UK is 4.8% of those over 65 years of age and 12.2% of those aged 80 years or more. There are around 70,000 new diagnoses in the UK each year .
Wet age-related macular degeneration